Hyperion Therapeutics
Acquired
- Headquarters
- South San Francisco, California
- Employees
- 51–200
- Business Model
- B2B
- Total Funding
- $117.5M
- Last Round
- $17.5M Venture RoundApr 2011
About
Hyperion Therapeutics was a Brisbane, CA-based commercial-stage biopharmaceutical company founded in 2006, focused on orphan diseases. The company developed and commercialized RAVICTI (glycerol phenylbutyrate) and BUPHENYL for urea cycle disorders. Hyperion went public on Nasdaq before being acquired by Horizon Pharma in May 2015 for approximately $1.1 billion.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account